Silver Spring, Maryland – The FDA’s Oncologic Drugs Advisory Committee voted in favor of supporting the approvals of CAR-T therapies as earlier lines of treatment for multiple myeloma. Johnson & Johnson, Legend Biotech, Bristol Myers Squibb, and 2seventyBio’s therapies were discussed during the meeting, with a focus on the risks associated with early deaths in … Read more
Washington, D.C. – The FDA has raised concerns over early deaths in clinical trials for CAR-T therapies used to treat myeloma, a type of blood cancer. The trials involved Johnson & Johnson and Legend’s Carvykti, as well as Bristol Myers’ Abecma. The FDA is closely monitoring these trials to ensure patient safety and efficacy of … Read more
After multiple myeloma was diagnosed in Judith Harding in 2009, she made drastic life changes, expecting the worst. Meanwhile, Bill McHugh underwent a stem cell transplant for the same type of blood cancer in 2013. Their survival was once considered exceptional, but thanks to recent advancements in treatment, they are now considered typical multiple myeloma … Read more